

Novachem Pty Ltd

Version No: 1.1

Safety Data Sheet according to WHS and ADG requirements

Chemwatch Hazard Alert Code: 4

Issue Date: **15/02/2018** Print Date: **15/02/2018** S.GHS.AUS.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	(±)-MDMA [(±)-3,4-Methylenedioxymethamphetamine]			
Chemical Name	3,4-methylenedioxymethamphetamine			
Synonyms	M-013			
Proper shipping name	METHANOL			
Chemical formula	C11-H15-N-O2			
Other means of identification	Not Available			
CAS number	42542-10-9*			

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Laboratory chemicals, Synthesis of substances
--------------------------	---

Details of the supplier of the safety data sheet

Registered company name	Novachem Pty Ltd
Address	25 Crissane Road, Heidelberg West Victoria 3081 Australia
Telephone	+61384151255
Fax	+61386250088
Website	www.novachem.com.au
Email	novachem@novachem.com.au

Emergency telephone number

Association / Organisation	Victorian Poisons Information Centre
Emergency telephone numbers	13 11 26
Other emergency telephone numbers	Not Available

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

Poisons Schedule	S6
Classification ^[1]	Flammable Liquid Category 2, Acute Toxicity (Oral) Category 3, Acute Toxicity (Dermal) Category 3, Acute Toxicity (Inhalation) Category 3, Specific target organ toxicity - single exposure Category 1
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex VI

Label elements

Hazard pictogram(s)	
SIGNAL WORD	DANGER

Hazard statement(s)

H225	Highly flammable liquid and vapour.
H301	Toxic if swallowed.
H311	Toxic in contact with skin.
H331	Toxic if inhaled.

H370 Causes damage to organs.

Precautionary statement(s) Prevention

• • • • • •				
P210	Keep away from heat/sparks/open flames/hot surfaces No smoking.			
P260	Do not breathe dust/fume/gas/mist/vapours/spray.			
P270	Do not eat, drink or smoke when using this product.			
P271	Use only outdoors or in a well-ventilated area.			

Precautionary statement(s) Response

· · · · · · · · · · · · · · · · · · ·				
P301+P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.			
P307+P311	IF exposed: Call a POISON CENTER or doctor/physician.			
P330	Rinse mouth.			
P363	Wash contaminated clothing before reuse.			

Precautionary statement(s) Storage

P403+P235	Store in a well-ventilated place. Keep cool.
P405	Store locked up.

Precautionary statement(s) Disposal

Dispose of contents/container in accordance with local regulations.

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

P501

Substances

CAS No	%[weight]	Name		
67-56-1	99.9	methanol		
42542-10-9	0.1	3,4-methylenedioxymethamphetamine		

Mixtures

See section above for composition of Substances

SECTION 4 FIRST AID MEASURES

Description	of	first	aid	measures
-------------	----	-------	-----	----------

Eye Contact	If this product comes in contact with the eyes: Immediately hold eyelids apart and flush the eye continuously with running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes. Transport to hospital or doctor without delay. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	 If skin or hair contact occurs: Quickly but gently, wipe material off skin with a dry, clean cloth. Immediately remove all contaminated clothing, including footwear. Wash skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Centre. Transport to hospital, or doctor.
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor, without delay.
Ingestion	 IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. For advice, contact a Poisons Information Centre or a doctor. Urgent hospital treatment is likely to be needed. In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition. If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist. If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS. Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise: INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. NOTE: Wear a protective glove when inducing vomiting by mechanical means. If spontaneous vomiting appears imminent or occurs, hold patient's head down, lower than their hips to help avoid possible aspiration of vomitus.

Indication of any immediate medical attention and special treatment needed

In the use of psychoactive substances, four recognised chronic reactions have been reported

Prolonged psychotic reactions

- Depression sufficiently severe to be life-threatening
- Flashbacks
- Exacerbation of pre-existing psychiatric illness

Some persons who have experienced many psychedelic trips, especially those who have had acute adverse reactions, develop what appears to be serious long-term personality disruption.

These prolonged psychotic reactions have similarities to schizophrenic reactions and appear to occur most often in persons with pre-existing psychological difficulties - primarily pre-psychotic or psychotic personalities

Psychedelic-induced personality disorders can be severe and prolonged.

Appropriate treatment often requires antipsychotic medication (antipsychotics, neuroleptics, major tranquillisers) and residential care in a mental health facility.

In certain cases, psychedelic-induced chronic psychological problems lead to complicated patterns of polydrug abuse that requires additional treatment approaches.

Note

Antipsychotics are associated with a range of side effects. It is well-recognized that many people stop taking them (around two-thirds even in controlled drug trials) due in part to adverse effects. Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control) and hyperprolactinaemia primarily in typical's and weight gain and metabolic abnormalities mostly in atypicals. Temporary withdrawal symptoms including insomnia, agitation, psychosis, and motor disorders may occur during dosage reduction of antipsychotics, and can be mistaken for the return of the underlying condition.

Many psychoactives are also monoamine oxidase inhibitors (MAOIs):

Special care should be taken with any drug therapy in view of the many hazards of monoamine oxidase inhibitor interactions. In particular metaraminol and other sympathomimetic agents are not suitable for the treatment of hypotension, which should be managed with intravenous fluids and, in severe shock, intravenous hydrocortisone

The management of overdose with amphetamines generally involves supportive and symptomatic therapy. Sedation is usually sufficient. Forced acid diuresis has been advocated to increase amphetamine excretion but should only be considered in severely poisoned patients and requires close supervision and monitoring. MARTINDALE: The Extra Pharmacopoeia, 27th Ed. Amphetamines may be monoamine oxidase inhibitors (MAOIs). Monoamine oxidase inhibitors produce postural hypotension, dizziness, drowsiness, weakness and fatigue, dryness of the mouth, constipation and other gastrointestinal disturbances (including nausea and vomiting) and oedema. Other symptoms may include agitation and tremors, insomnia and restless sleep, blurred vision, difficulty in urinating, convulsions, skin rashes, leucopenia, sexual disturbances and weight gain with inappropriate appetite. Psychotic episodes may be characterised by hypomanic behavior, confusion and hallucinations. Jaundice has been reported and infrequently this may lead to fatal progressive hepatocellular necrosis for stimulants:

Treatment and Management.

A specific antidote does not exist for acute stimulant intoxication. Activated charcoal should be prescribed in a case of acute overdose. Otherwise the treatment should target specific signs and symptoms such as hypertension, agitation, seizures, and hyperthermia. Rapid supportive treatment may reduce mortality.

Supportive therapy

Acute intoxication usually presents with increased sensitivity to sensorial stimuli and paranoia. As such, decreasing the patient's level of stimulation (keep voice low, dim lights, minimise touch) and working with the patient's paranoid state (reduce eye contact, respect personal space, do not approach from behind) is important.

As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).

Decontamination with gastric lavage may be appropriate in cases of recent ingestion.

Monitor vital signs and hydrate with intravenous fluids.

Withdrawal related insomnia may be treated with trazodone (75-200 mg), hydroxyzine (25-50 mg), or diphenhydramine (50-100 mg) at bedtime.

Benzodiazepines should be avoided unless the patient is also in detox from alcohol/benzodiazepines/opiates.

Neuroleptics may be used for the symptomatic treatment of psychosis. Physical restraints may be required in certain cases.

Common withdrawal symptoms may include dysphoria, anxiety, and irritability, decreased energy (manifested as reported fatigue, psychomotor retardation and hypersonnia), hyperphagia, decreased concentration, and paranoia. The withdrawal symptoms are uncomfortable but not life threatening; consequently, no current recommendations for a stimulant-detoxification regimen are available

Stimulant withdrawal dysphoria is common and does not in itself represent an indication for an antidepressant. However, a thorough assessment (including consideration of an antidepressant) is recommended for persistent (longer than a week) depressive symptoms at a level of moderate or severe or associated with suicidal ideation/attempts

Treatment of overdose of oral sympathomimetics should be symptomatic and supportive and may include the following:

1. Consider gastric lavage within one hour of ingestion. Induced vomiting may not be advisable because of the potential for seizures and worsening hypertension.

2. Administer activated charcoal slurry.

Medscape

3. Monitor EKG, ECG, serum electrolytes, blood sugar, blood pressure, urinary output, and renal function. Pharmacological action is required only in severely symptomatic patients.

4. For pulmonary edema (noncardiogenic) - Maintain ventilation and oxygenation with close arterial blood gas monitoring.

- 5. For seizures or severe agitation Administer benzodiazepines
- 6. For dystonic reactions Administer benzotropine or diphenhydramine.
- 7. For ventricular tachycardia Administer lidocaine.
- 8. For severe hypertension Nitroprusside, labetalol, or phentolamine may be necessary.
- 9. For hypotension Infuse patient with isotonic solution; if condition persists, administer dopamine or norepinephrine.

10. For rhabdomyolosis - Administer sufficient 0.9% saline to maintain urine output of 2 to 3 l/kg/hour. Diuretics may be necessary; urinary alkalinization is NOT routinely recommended.

- 11. For hyperthermia Manage with external cooling; avoid phenothiazines. [Meditext 2006]
- For acute and short term repeated exposures to methanol:
- Toxicity results from accumulation of formaldehyde/formic acid.
- Clinical signs are usually limited to CNS, eyes and GI tract Severe metabolic acidosis may produce dyspnea and profound systemic effects which may become intractable. All symptomatic patients should have arterial pH measured. Evaluate airway, breathing and circulation.
- Stabilise obtunded patients by giving naloxone, glucose and thiamine.
- Decontaminate with Ipecac or lavage for patients presenting 2 hours post-ingestion. Charcoal does not absorb well; the usefulness of cathartic is not established.
- Forced diuresis is not effective; haemodialysis is recommended where peak methanol levels exceed 50 mg/dL (this correlates with serum bicarbonate levels below 18 meq/L).
- > Ethanol, maintained at levels between 100 and 150 mg/dL, inhibits formation of toxic metabolites and may be indicated when peak methanol levels exceed 20 mg/dL. An intravenous solution of ethanol in D5W is optimal.
- Folate, as leucovorin, may increase the oxidative removal of formic acid. 4-methylpyrazole may be an effective adjunct in the treatment. 8.Phenytoin may be preferable to diazepam for controlling seizure

[Ellenhorn Barceloux: Medical Toxicology]

BIOLOGICAL EXPOSURE INDEX - BEI

Determinant	Index	Sampling Time
1. Methanol in urine	15 mg/l	End of shift
2. Formic acid in urine	80 mg/gm creatinine	Before the shift at end of workweek

B: Background levels occur in specimens collected from subjects NOT exposed.

NS: Non-specific determinant - observed following exposure to other materials

Commen B. NS

B. NS

Version No: 1.1

Issue Date: 15/02/2018 Print Date: 15/02/2018

(±)-MDMA [(±)-3,4-Methylenedioxymethamphetamine]

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media

- Water may be an ineffective extinguishing media for methanol fires; static explosions are reported for aqueous solutions as dilute as 30%. Water may be used to cool containers.
- Alcohol stable foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

-	
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area.
Fire/Explosion Hazard	 Combustible. Slight fire hazard when exposed to heat or flame. Heating may cause expansion or decomposition leading to violent rupture of containers. On combustion, may emit toxic fumes of carbon monoxide (CO). Combustion products include: carbon dioxide (CO2) formaldehyde other pyrolysis products typical of burning organic material. May emit poisonous fumes.
HAZCHEM	•2WE

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	 Remove all ignition sources. Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. May be violently or explosively reactive. Wear full body protective clothing with breathing apparatus.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

Safe handling	 Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps.
Other information	 NOTE: Special security requirements may be mandated under Federal/State Regulation(s). Store in original containers. Store in vault fitted with warning devices or detectors recommended by various Federal/State authorities. Store in vault used only for the purpose of storage of drugs of addiction.

Conditions for safe storage, including any incompatibilities

Suitable container	 Packaging as recommended by manufacturer. Check that containers are clearly labelled. Tamper-proof containers. Polyethylene or polypropylene containers. Glass container is suitable for laboratory quantities For low viscosity materials Drums and jerricans must be of the non-removable head type. Where a can is to be used as an inner package, the can must have a screwed enclosure. For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.): Removable head packaging; Cans with friction closures and Iow pressure tubes and cartridges

may be used.

Storage incompatibility	 Methanol: reacts violently with strong oxidisers, acetyl bromide, alkyl aluminium salts, beryllium dihydride, bromine, chromic acid, 1-chloro-3,3-diffuoro-2-methoxycyclopropene, cyanuric chloride, diethylzinc, isophthaloyl chloride, nitric acid, perchloric acid, potassium-tert-butoxide, potassium sulfur dimide, Raney nickel catalysts, 2,4,6-trichlorotrizaine, triethylaluminium, 1,3,3-triffuoro-2-methoxycyclopropene is incompatible with strong acids, strong caustics, alkaline earth and alkali metals, aliphatic amines, acetaldehyde, benzoyl peroxide, 1,3-bis(din-n-cyclopentadienyl iron)-2-propen-1-one, calcium carbide, chloroform, chromic anhydride, chromium trioxide, dialkylzinc, dichlorine oxide, dichloromethane, ethylene oxide, hypochlorous acid, isocyanates, isopropyl chlorocarbonate, lithium tetrahydroaluminate, magnesium, methyl azide, nitrogen dioxide, palladium, pentafluoroguanidine, perchloryl fluoride, phosphorus pentasulfide, phosphorus trioxide, potassium, tangerine oil, triisobutylaluminium mixtures with lead perchlorate, sodium hypochlorite are explosive may react with metallic aluminium at high temperatures slowly corrodes lead and aluminium may generate electrostatic charges, due to low conductivity, on flow or agitation attack some plastics, rubber and coatings. Static induced flash fires have happened when filling plastic containers with methanol / water solutions with as low as 30% methanol content Alcohols are incompatible with strong acids, acid chlorides, acid anhydrides, oxidising and reducing agents. reacts, possibly violently, with alkaline metals and alkaline earth metals to produce hydrogen react with strong acids, strong caustics, aliphatic amines, isocyanates, acetaldehyde, benzoyl peroxide, chromic acid, chromium oxide, dialkylzincs, dichlorine oxide, ethylene oxide, hypochlorous acid, isopropyl chlorocarbonate, lithium tetrahydroaluminate, nitrogen dioxide, pentafluoroguanidin
-------------------------	--

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Ingredient	Material name	TWA		STEL		Peak		Notes
methanol	Methyl alcohol	262 mg/m3	3 / 200 ppm	328 mg/m	3 / 250 ppm	Not Availal	ble	Not Available
Material name			TEEL-1		TEEL-2		TEEL-3	
Methyl alcohol; (Me	ethanol)		Not Available		Not Available		Not Ava	ilable
Original IDLH				Revised	IDLH			
6000 ppm				Not Availa	ible			
Not Available				Not Availa	ıble			
	methanol Material name Methyl alcohol; (M Original IDLH 6000 ppm	methanol Methyl alcohol Material name Methyl alcohol; (Methanol) Original IDLH 6000 ppm	methanol Methyl alcohol 262 mg/m Material name Methyl alcohol; (Methanol) Original IDLH	Material name TEEL-1 Material name Not Available Original IDLH 6000 ppm	Methyl alcohol 262 mg/m3 / 200 ppm 328 mg/m3 Material name TEEL-1 Methyl alcohol; (Methanol) Not Available Original IDLH Revised 6000 ppm Not Available	Methyl alcohol 262 mg/m3 / 200 ppm 328 mg/m3 / 250 ppm Material name TEEL-1 TEEL-2 Methyl alcohol; (Methanol) Not Available Not Available Original IDLH Revised IDLH 6000 ppm Not Available	Methyl alcohol 262 mg/m3 / 200 ppm 328 mg/m3 / 250 ppm Not Available Material name TEEL-1 TEEL-2 Methyl alcohol; (Methanol) Not Available Not Available Original IDLH Revised IDLH Not Available	Methyl alcohol 262 mg/m3 / 200 ppm 328 mg/m3 / 250 ppm Not Available Material name TEEL-1 TEEL-2 TEEL-3 Methyl alcohol; (Methanol) Not Available Not Available Not Available Original IDLH Revised IDLH E E

Exposure controls

-	
Appropriate engineering controls	 For potent pharmacological agents: Solutions Handling: Solutions can be handled outside a containment system or without local exhaust ventilation during procedures with no potential for aerosolisation. If the procedures have a potential for aerosolisation, an air-purifying respirator is to be worn by all personnel in the immediate area. Solutions used for procedures where aerosolisation may occur (e.g., vortexing, pumping) are to be handled within a containment system or with local exhaust ventilation. In situations where this is not feasible (may include animal dosing), an air-purifying respirator is to be worn by all personnel in the immediate area. Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation. HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours. Barrier protection or laminar flow cabinets should be considered for laboratory scale handling. A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg.
Personal protection	
Eye and face protection	 Chemical protective goggles with full seal. Shielded mask (gas-type). Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task.
Skin protection	See Hand protection below
	The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application. The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final
Hands/feet protection	 choice. Personal hygiene is a key element of effective hand care. Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference. Double gloving should be considered. PVC gloves.

Version No: 1.1

(±)-MDMA [(±)-3,4-Methylenedioxymethamphetamine]

Other protection	 For quantities up to 500 grams a laboratory coat may be suitable. For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs. For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
Thermal hazards	Not Available

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

(±)-MDMA [(±)-3,4-Methylenedioxymethamphetamine]

Material	CPI
BUTYL	A
BUTYL/NEOPRENE	A
PE/EVAL/PE	A
PVDC/PE/PVDC	A
SARANEX-23 2-PLY	А
SARANEX-23	А
TEFLON	A
VITON/NEOPRENE	А
NEOPRENE	В
NAT+NEOPR+NITRILE	С
NATURAL RUBBER	С
NATURAL+NEOPRENE	С
NEOPRENE/NATURAL	С
NITRILE	С
PVA	С
PVC	С

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final

selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as

"feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise

be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Not Available		
Physical state	Liquid	Relative density (Water = 1)	0.79 @ 20 C
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	385- (464 ICI)
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	-97.8	Viscosity (cSt)	0.59
Initial boiling point and boiling range (°C)	64-65	Molecular weight (g/mol)	32.04
Flash point (°C)	11-12(16.1 OC)	Taste	Not Available
Evaporation rate	2.1 BuAc=1 BuAC = 1	Explosive properties	Not Available
Flammability	HIGHLY FLAMMABLE.	Oxidising properties	Not Available
Upper Explosive Limit (%)	36	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	6	Volatile Component (%vol)	ca 100 @ 20 C
Vapour pressure (kPa)	12.26 @ 20 C	Gas group	Not Available
Solubility in water (g/L)	Miscible	pH as a solution (1%)	Neutral
Vapour density (Air = 1)	1.1	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Respiratory protection

Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content. The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class	-
		1	
up to 50	1000	-	A-AUS / Class
			1
up to 50	5000	Airline *	-
up to 100	5000	-	A-2
up to 100	10000	-	A-3
100+		-	Airline**

* - Continuous Flow

** - Continuous-flow or positive pressure demand.

A(All classes) = Organic vapours, B AUS or B1 = Acid gases, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 deg C)

Reactivity	See section 7
Chemical stability	 Static induced flash fires have happened when filling plastic containers with methanol / water solutions with as low as 30% methanol content. Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	There is strong evidence to suggest that this material can cause, if inhaled once, very serious, irreversible damage of organs. The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Minor but regular methanol exposures may effect the central nervous system, optic nerves and retinae. Symptoms may be delayed, with headache, fatigue, nausea, blurring of vision and double vision. Continued or severe exposures may cause damage to optic nerves, which may become severe with permanent visual impairment even blindness resulting. WARNING : Methanol is only slowly eliminated from the body and should be regarded as a cumulative poison which cannot be made non-harmful [<i>CCINFO</i>] Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may produce toxic effects.			
Ingestion	Toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 40 gram may be fatal or may produce serious damage to the health of the individual. Swallowing of MDMA may result in elation, greater self-esteem, empathy, increased energy, dizziness, disorientation and, less frequently, hallucinations. There may be a prolonged psychotic reaction. Rapid eye oscillation, muscle spasm, slight tightening of the jaw, increased heart rate and blood pressure, nausea, vomiting, sweating, pupil dilation and difficulty sleeping may last for several weeks. Death have occurred, sometimes even after one dose. Psychedelic states are a group of experiences including changed perception such as hallucinations, synaesthesia, altered awareness or focused consciousness, change in thought patterns, trance or hypnotic states and mystical states. This can lead to changes in self-identity and cause feelings of revelation, enlightemment, confusion and psychosis. Psychedelic states may be caused by meditation, sensory stimulation or deprivation, and, most commonly, by the use of psychedelic substances. When used for spiritual purposes they are called entheogens. Phenethylamines produce effects similar to amphetamines. They excite the nervous system, causing shortness of breath, cough, narrowing of the airways and throat spasms. Adverse effects associated with the administration of central nervous system stimulants include shortness of breath, coughing, spasm of the bronchi and spasm of the throat (larynx). Muscular involvement may produce symptoms ranging from twitching to spasticity or seizures. Headache, dizziness and confusion may also result, as can a very high fever or a sensation of the central nervous system and include sleeplessness, nervousness, restlessness, intiability and a feeling of well-being, followed by fatigue and depression. There may be dry mouth, poor appetite, abdominal cramps and other gastrointestinal disturbances, hedache, dizziness, termor, sweating,			
Skin Contact	Skin contact with the material may produce toxic effects; systemic effects may result following absorption. The material is not thought to be a skin irritant (as classified by EC Directives using animal models). Temporary discomfort, however, may result from prolonged dermal exposures. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. There is strong evidence to suggest that this material, on a single contact with skin, can cause serious, irreversible damage of organs.			
Eye	Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn). 510meth			
Chronic	Long-term exposure to the product is not thought to produce chronic effects adverse to the health (as classified by EC Directives using animal models); nevertheless exposure by all routes should be minimised as a matter of course. Long-term use of amphetamines can lead to tolerance developing to some of its effects, leading to an urge to increase dose and habituation. However, amphetamines generally do not cause physical dependence. Exposure to 3,4-methylenedioxymethamphetamine (MDMA) has caused long-term, irreversible damage to the central nervous system. Chronic administration produces severe depletion of serotonin reserves.			
Chronic	Long-term exposure to methanol vapour, at concentrations exceeding 3000 ppm, may produce cumulative effects characterised by gastrointestinal disturbances (nausea, vomiting), headache, ringing in the ears, insomnia, trembling, unsteady gait, vertigo, conjunctivitis and clouded or double vision. Liver and/or kidney injury may also result. Chronic exposure to phenethylamines excite the central nervous system and induce tolerance; in extreme cases they produce amphetamine-like responses including personality changes, compulsive and stereotyped behaviour and may induce psychosis with auditory and visual hallucinations and paranoid delusions.			
(±)-MDMA [(±)- Methylenedioxymethamphetam		IRRITATION Not Available		

		ΤΟΧΙΟΙΤΥ		IRRITATION	
		Dermal (rabbit) LD50: 15800 mg/kg ^[2]		Eye (rabbit): 100 mg/24h-moderate	
metha	inol	Inhalation (rat) LC50: 63926.976 mg/l/4h ^[2]		Eye (rabbit): 40 mg-moderate	
		Oral (rat) LD50: 5600 mg/kg ^[2]		Skin (rabbit): 20 mg/24 h-moderate	
3,4-methylenedioxymethamphetamine		TOXICITY IRRITATION		TATION	
		Not Available	Not Available		
Legend:		alue obtained from Europe ECHA Registered Substances - Acute toxicity 2.* a extracted from RTECS - Register of Toxic Effect of chemical Substances	Value	obtained from manufacturer's SDS. Unless otherwise specified	

METHANOL		The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles, scaling and thickening of the skin.				
3,4-METHYLENEDIOXYMETHAMPHETAMINE		No significant acute toxicological data identified in literature search. Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis). Degenerative changes in the brain recorded.				
Acute Toxicity	~		Carcinogenicity	0		
Skin Irritation/Corrosion	\otimes		Reproductivity	0		
Serious Eye Damage/Irritation	\odot		STOT - Single Exposure	✓		
Respiratory or Skin sensitisation	\odot		STOT - Repeated Exposure	0		
Mutagenicity	\odot		Aspiration Hazard	\odot		
	-		- S	Data available but does not fill the criteria for classification Data available to make classification		

S - Data Not Available to make classification

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

(±)-MDMA [(±)-3,4-	ENDPOINT		TEST DURATION (HR)		SPECIES VALUE			SOURCE
Methylenedioxymethamphetamine]	Not Available		Not Available		Not Available Not Avail		vailable Not Available	
	ENDPOINT	TE	ST DURATION (HR)	SPECIES			VALUE	SOURCE
methanol	LC50	96		Fish			>100mg/L	4
	EC50	48		Crustacea			>10000mg/L	4
	EC50	96		Algae or other aquatic plants			<10000mg/L	4
	BCF	24		Algae or other aquatic plants			0.05mg/L	4
	EC0	168		Algae or other aquatic plants			=530mg/L	1
	NOEC	72		Crustacea		0.1mg/L	4	
3,4-methylenedioxymethamphetamine	ENDPOINT		TEST DURATION (HR)	SPECIES		VALUE		SOURCE
	Not Available		Not Available		Not Available Not Avai		ilable Not Available	

Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12
	(QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE
	(Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

For Methanol: Log Kow: -0.82 to -0.66; Koc: 1; Henry I s Law Constant: 4.55x10-6 atm-cu m/mole; Vapor Pressure: 127 mm Hg; BCF: < 10.

Atmospheric Fate: Methanol is expected to exist solely as a vapor in the ambient atmosphere. Vapor-phase methanol is broken down in the atmosphere by reactions with hydroxyl radicals; the half-life for this reaction in air is estimated to be 17 days.

Terrestrial Fate: Methanol is expected to have very high mobility in soil.

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
methanol	LOW	LOW
3,4-methylenedioxymethamphetamine	HIGH	HIGH

Bioaccumulative potential

Ingredient	Bioaccumulation
methanol	LOW (BCF = 10)

Version No: 1.1

(±)-MDMA [(±)-3,4-Methylenedioxymethamphetamine]

3,4-methylenedioxymethamphetamine LOW (LogKOW = 2.1637)

Mobility in soil

mobility in son	
Ingredient	Mobility
methanol	HIGH (KOC = 1)
3,4-methylenedioxymethamphetamine	LOW (KOC = 501.6)

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods Containers may still present a chemical hazard/ danger when empty. Return to supplier for reuse/ recycling if possible. Otherwise: > If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. • Where possible retain label warnings and SDS and observe all notices pertaining to the product. Valuable substance, hold all residues for recovery. Disposal of the material must be carried out in accordance with the requirements of the relevant Federal/State Act(s) or Code(s) regulating the disposal of Drugs of Addiction. Consult manufacturer/supplier for recycling options. • Decontaminate empty containers with water; incinerate plastic bags. Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In Product / Packaging disposal some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate: Reduction Reuse Recycling Disposal (if all else fails) This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. • DO NOT allow wash water from cleaning or process equipment to enter drains. It may be necessary to collect all wash water for treatment before disposal. In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ۲ • Where in doubt contact the responsible authority.

SECTION 14 TRANSPORT INFORMATION

Labels Required

	3
Marine Pollutant	NO
HAZCHEM	•2WE

Land transport (ADG)

UN number	1230	
UN proper shipping name	METHANOL	
Transport hazard class(es)	Class3Subrisk6.1	
Packing group	ll de la constante de la const	
Environmental hazard	Not Applicable	
Special precautions for user	Special provisions279Limited quantity1 L	

Air transport (ICAO-IATA / DGR)

UN number	1230		
UN proper shipping name	Methanol		
Transport hazard class(es)	ICAO/IATA Class ICAO / IATA Subrisk ERG Code	3 6.1 3L	
Packing group	Ш		
Environmental hazard	Not Applicable		

	Special provisions	A113
	Cargo Only Packing Instructions	364
	Cargo Only Maximum Qty / Pack	60 L
Special precautions for user	Passenger and Cargo Packing Instructions	352
	Passenger and Cargo Maximum Qty / Pack	1 L
	Passenger and Cargo Limited Quantity Packing Instructions	Y341
	Passenger and Cargo Limited Maximum Qty / Pack	1 L

Sea transport (IMDG-Code / GGVSee)

UN number	1230		
UN proper shipping name	METHANOL		
Transport hazard class(es)	IMDG Class3IMDG Subrisk6.1		
Packing group	II		
Environmental hazard	Not Applicable		
Special precautions for user	EMS NumberF-E, S-DSpecial provisions279Limited Quantities1 L		

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

 METHANOL(67-56-1) IS FOUND ON THE FOLLOWING REGULATORY LISTS

 Australia Exposure Standards
 Australia Inventory of Chemical Substances (AICS)

Australia Hazardous Substances Information System - Consolidated Lists

3,4-METHYLENEDIOXYMETHAMPHETAMINE(42542-10-9) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Not Applicable	
National Inventory	Status
Australia - AICS	N (3,4-methylenedioxymethamphetamine)
Canada - DSL	N (3,4-methylenedioxymethamphetamine)
Canada - NDSL	N (methanol; 3,4-methylenedioxymethamphetamine)
China - IECSC	N (3,4-methylenedioxymethamphetamine)
Europe - EINEC / ELINCS / NLP	N (3,4-methylenedioxymethamphetamine)
Japan - ENCS	N (3,4-methylenedioxymethamphetamine)
Korea - KECI	N (3,4-methylenedioxymethamphetamine)
New Zealand - NZIoC	N (3,4-methylenedioxymethamphetamine)
Philippines - PICCS	N (3,4-methylenedioxymethamphetamine)
USA - TSCA	N (3,4-methylenedioxymethamphetamine)
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Ingredients with multiple cas numbers

Name	CAS No
3,4-methylenedioxymethamphetamine	42542-10-9, 54946-52-0

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average

PC – STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit, IDLH: Immediately Dangerous to Life or Health Concentrations OSF: Odour Safety Factor NOAEL : No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value

BCF: BioConcentration Factors

BEI: Biological Exposure Index

Powered by AuthorITe, from Chemwatch.

